DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The "Nephrotic Syndrome - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Nephrotic Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 1 and 3 respectively.

Companies Mentioned

Asahi Kasei Pharma Corp Aurinia Pharmaceuticals Inc Bristol-Myers Squibb Co Orbis Biosciences Inc Pfizer Inc

Key Topics Covered

Introduction Report Coverage Nephrotic Syndrome - Overview Nephrotic Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Nephrotic Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Nephrotic Syndrome - Companies Involved in Therapeutics Development Asahi Kasei Pharma Corp Aurinia Pharmaceuticals Inc Bristol-Myers Squibb Co Orbis Biosciences Inc Pfizer Inc Nephrotic Syndrome - Drug Profiles abatacept - Drug Profile Product Description Mechanism Of Action R&D Progress mizoribine - Drug Profile Product Description Mechanism Of Action R&D Progress PF-06730512 - Drug Profile Product Description Mechanism Of Action R&D Progress prednisone - Drug Profile Product Description Mechanism Of Action R&D Progress voclosporin - Drug Profile Product Description Mechanism Of Action R&D Progress Nephrotic Syndrome - Dormant Projects Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation

For more information about this report visit https://www.researchandmarkets.com/research/mnbcn6/2018_nephrotic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006405/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 12:42 PM/DISC: 06/05/2018 12:42 PM

http://www.businesswire.com/news/home/20180605006405/en